Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation
Director departure

RVL Pharmaceuticals plc (OSMT) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
06/06/2019 8-K Investor presentation
Docs: "Investor Presentation"
05/21/2019 8-K Investor presentation
Docs: "Investor Presentation"
05/07/2019 8-K Investor presentation
Docs: "Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 for Acquired Blepharoptosis - Second Phase III Study 202 Meets Primary Endpoint; Provides Additional Evidence of Efficacy and Safety - - Long-term Phase III Study 203 Provides Additional Evidence of Safety - - Company to Host Conference Call on Tuesday, May 7th at 12pm ET with Dr. Chuck Slonim and Dr. Shane Kannarr -",
"Investor Presentation"
12/04/2018 8-K Investor presentation
Docs: "Investor Presentation"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy